FOLLICULAR HELPER T-CELL LYMPHOMA
Clinical trials for FOLLICULAR HELPER T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new FOLLICULAR HELPER T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for FOLLICULAR HELPER T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare lymphoma: targeted drug plus chemo enters first human tests
Disease control Not yet recruitingThis early-phase trial tests whether adding the targeted drug ruxolitinib to standard chemotherapy (CHOP) is safe and effective for people with untreated nodal T-follicular helper (TFH) cell lymphoma, a rare blood cancer. About 20 adults will take part to find the best dose and w…
Matched conditions: FOLLICULAR HELPER T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New drug duvelisib aims to keep rare lymphoma at bay after first treatment
Disease control Not yet recruitingThis study tests whether the drug duvelisib can help keep peripheral T-cell lymphoma from returning after initial therapy has made it disappear. About 25 adults with certain types of this rare lymphoma will take duvelisib as a maintenance treatment. The goal is to see if it exten…
Matched conditions: FOLLICULAR HELPER T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 04, 2026 16:29 UTC